Efficacy and Safety of Lumiracoxib in Patients With Knee Osteoarthritis (OA).
Launched by NOVARTIS · Aug 21, 2006
Trial Information
Current as of May 20, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Primary osteoarthritis of knee (confirmed by American College of Rheumatology \[ACR\] criteria).
- • Requirement of regular non-steroidal anti-inflammatory drug (NSAID) therapy.
- Exclusion Criteria:
- • Evidence of active gastrointestinal ulceration within 12 months prior to the screening visit or history of active gastrointestinal bleeding within the previous 5 years.
- • Known hypersensitivity to analgesics, antipyretics, or NSAIDS (including celecoxib).
- • Other protocol-defined inclusion/exclusion criteria may apply.
About Novartis
Novartis is a global healthcare company based in Switzerland, dedicated to reimagining medicine to improve and extend people's lives. With a strong focus on innovative pharmaceuticals, Novartis engages in the research, development, and commercialization of a wide range of therapies across various therapeutic areas, including oncology, cardiology, immunology, and neuroscience. The company is committed to advancing clinical research through rigorous trials that prioritize patient safety and efficacy, aiming to deliver groundbreaking treatments and solutions that address unmet medical needs worldwide. Novartis's commitment to innovation and collaboration positions it at the forefront of the biopharmaceutical industry, driving advancements that enhance patient care and health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
E. Hanover, New Jersey, United States
Patients applied
Trial Officials
Novartis Pharmaceuticals
Study Chair
Novartis
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials